从CyBorD到达雷妥尤单抗-CyBorD:AL淀粉样变性自体干细胞移植利用趋势的15年分析
该回顾性分析纳入梅奥诊所2010至2024年间441例AL淀粉样变性自体干细胞移植(ASCT),分为2010-2019年队列1和2020-2024年队列2。队列2的ASCT数量显著减少(385例 vs 56例,年均下降71%),患者更年长、更多为复发/难治性疾病且骨髓浆细胞负荷更高;队列2诱导治疗更常见(89.3% vs 56.4%),达雷妥尤单抗-CyBorD取代CyBorD成为主要诱导方案;第100天满意血液学缓解率提高(91.1% vs 72.7%,P=0.001),但完全缓解率无显著差异(50.9% vs 38.8%,P=0.09)。
要点
- 队列2的ASCT数量较队列1显著减少(385例 vs 56例,年均下降71%)。
- 队列2诱导治疗更常见(89.3% vs 56.4%),达雷妥尤单抗-CyBorD成为主要方案。
- 第100天满意血液学缓解率队列2高于队列1(91.1% vs 72.7%,P=0.001)。
核心结论
- AL淀粉样变性中ASCT的使用减少,该操作主要保留给缓解欠佳、复发/难治性疾病、淋浆细胞克隆(主要为免疫球蛋白M淀粉样变性)或高骨髓浆细胞负荷(骨髓瘤表型)的患者。
- 本研究强调由新型疗法驱动的ASCT实践显著转变,突出AL淀粉样变性更个性化的管理。
研究设计与样本
- 梅奥诊所2010至2024年15年间AL淀粉样变性ASCT的回顾性分析。
- 共441例ASCT,分为队列1(2010-2019年)和队列2(2020-2024年)。
主要发现
- 队列2的ASCT数量显著减少(385例 vs 56例,年均下降71%)。
- 队列2患者更年长、更多为复发/难治性疾病,且基线骨髓浆细胞负荷高于队列1。
- 队列2的ASCT前诱导治疗更常见(89.3% vs 56.4%),达雷妥尤单抗-CyBorD取代CyBorD成为主要诱导方案。
- 队列2基于淋巴瘤的方案也更常见(15.1% vs 5.3%,P=0.02)。
- 第100天满意血液学缓解率队列2高于队列1(91.1% vs 72.7%,P=0.001),但血液学完全缓解率无显著差异(50.9% vs 38.8%,P=0.09)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This retrospective analysis examined 15 years of autologous stem cell transplantation (ASCT) for light chain (AL) amyloidosis at the Mayo Clinic (2010-2024). We aimed to assess ASCT utilization trends, factors influencing practice changes, and current indications amid newer therapies. Four hundred and forty-one ASCTs were divided into cohort 1 (2010-2019) and cohort 2 (2020-2024), revealing a significant ASCT reduction in cohort 2 (385 vs 56, average 71% annual decrease). Cohort 2 patients were older, more likely to have relapsed/refractory disease, and had higher baseline bone marrow plasma cell burden compared to cohort 1. Pre-ASCT induction was more frequent in cohort 2 (89.3% vs 56.4%), with daratumumab (Dara)-cyclophosphamide-bortezomib-dexamethasone (CyBorD) replacing CyBorD as the predominant induction regimen. Lymphoma-based regimens were also more common in cohort 2 (15.1% vs 5.3%, P = .02). Day-100 satisfactory hematological response improved in cohort 2 (91.1% vs 72.7%, P = .001), although hematological complete response rates did not significantly differ (50.9% vs 38.8%, P = .09). In summary, there is a decrease in the utilization of ASCT in AL amyloidosis. This procedure is primarily reserved for patients with suboptimal responses, relapsed/refractory disease, lymphoplasmacytic clones (predominantly immunoglobulin M amyloidosis), or high bone marrow plasma cell burden (myeloma phenotype). This study underscores a significant shift in ASCT practice, driven by novel therapies, emphasizing more personalized management in AL amyloidosis.
引用
- Muchtar E, Dispenzieri A, Buadi FK, et al. From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis. Blood Adv. 2025. PMID: 40590881. doi:10.1182/bloodadvances.2025016586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。